Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
BörsenkürzelCUPR
Name des UnternehmensCuprina Holdings (Cayman) Ltd
IPO-datumApr 10, 2025
CEOMr. Yong Qi (David) Quek
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 10
AddresseBlock 1090
Stadt
BörseNASDAQ Capital Market Consolidated
LandSingapore
Postleitzahl169201
Telefon6585127275
Websitehttps://cuprina.com/
BörsenkürzelCUPR
IPO-datumApr 10, 2025
CEOMr. Yong Qi (David) Quek
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten